Nicox Highlights Recent Progress with Key Programs and Activities

June 29, 2018

Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and highlighted recent progress with key programs and activities.

As expected, the first half of 2018 has seen important progress with our primary research and development projects,” said Michele Garufi, Chairman and Chief Executive Officer of Nicox.In addition, we know that Bausch + Lomb are putting significant efforts into the marketing of VYZULTA in the United States, with May prescriptions exceeding 4,400 scripts1. The manufacturing and scale-up of ZERVIATE is proceeding on track to support a fall 2018 commercial launch in the United States.

Preparations for the clinical studies evaluating NCX 470 for patients with glaucoma and NCX 4251 for patients with blepharitis are progressing as planned to support IND submissions during the third quarter of this year and first quarter of next year, respectively. Moreover, we have initiated our collaboration with Ironwood Pharmaceuticals, Inc. focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and our proprietary NO-donating research platform to generate new molecules with therapeutic potential; as well as progressed in our collaboration with Re-Vana. We are therefore optimistic about the evolution of our entire pipeline in the near future.

Key Upcoming Milestones

  • July 2018: Revenue update for Q2 2018
  • Q3 2018: Planned U.S. Investigational New Drug (IND) submission for NCX 470 for the treatment of patients with glaucoma
  • Fall 2018: Expected ZERVIATETM U.S. commercial launch
  • Q1 2019: Planned U.S. IND submission for NCX 4251 for the treatment of patients with blepharitis

Progress on Key Activities

  • Commercialization of VYZULTA® in the United States. The product has now been in the market for over 6 months and Q2 2018 revenue for Nicox is expected to be announced in mid-July.
  • ZERVIATETM expected to be launched in the U.S. by our partner Eyevance Pharmaceuticals during fall of 2018. Indicated for the treatment of ocular itching associated with allergic conjunctivitis, ZERVIATETM is the first and only topical ocular formulation of cetirizine.
  • NCX 470 U.S. IND submission enabling Phase 2 clinical study in glaucoma patients planned in Q3 2018. NCX 470 is a novel second generation NO-donating prostaglandin analog in development for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.
  • Additional pre-IND meeting held on NCX 4251 supporting the U.S. IND submission enabling Phase 2 clinical study in blepharitis patients planned in Q1 2019. In June 2018, an additional pre-IND meeting, which addressed specific questions on the potential primary endpoints for the Phase 2 study, was held with the U.S. FDA. Based on the FDA comments from this and previous meetings, we are finalizing the design of a first in human Phase 2 clinical trial. NCX 4251 is a novel, patented ophthalmic suspension of fluticasone propionate which is being developed for the first time as a targeted topical treatment of the eyelids for patients with acute exacerbation of blepharitis.
  • Research Collaboration with Ironwood Pharmaceuticals, Inc. In June 2018, we announced that we had entered into a research collaboration agreement with Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and our proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new therapeutics for the treatment of certain ophthalmic conditions.
  • Increasing the focusing of collaboration in extended release intraocular drug delivery for stand-alone NO-donors. We have decided to focus on our collaboration with Re-Vana Therapeutics concerning biodegradable extended release technologies and have discontinued the collaboration with Eyepoint Pharmaceuticals (previously pSivida) in this area.

Change to Nicox Board of Directors

Birgit Stattin Norinder, after seven years as member of Nicox’s Board of Directors, has decided to step down from the Board of Directors to pursue other projects, with effect as of 20 June 2018. The entire Nicox team would like to thank Birgit Stattin Norinder for her valuable contribution.


1. Bloomberg – June 27. 2018

← Back to blog page